Delving into the Latest Updates on VSA012 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

VSA012

Target-

Mechanism-

Therapeutic Areas

Hemic and Lymphatic DiseasesOther Diseases

Active Indication

Hemoglobinuria, Paroxysmal

Inactive Indication-

Originator Organization

Wei Ya Zhen Sheng Wu Ji Shu （ Su Zhou ） You Xian Gong Si

Active Organization

Wei Ya Zhen Sheng Wu Ji Shu （ Su Zhou ） You Xian Gong SiVisirna Therapeutics HK Limited

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Primary objective: To evaluate the safety and tolerability of a single subcutaneous injection of VSA012 in healthy subjects. Secondary objective: To evaluate the pharmacokinetics (PK) of VSA012 in plasma, the pharmacodynamics (PD) of VSA012 in serum and the immunogenicity characteristics of VSA012 after a single subcutaneous injection of VSA012 in healthy subjects.

Start Date-

Sponsor / Collaborator

Wei Ya Zhen Sheng Wu Ji Shu （ Su Zhou ） You Xian Gong Si

100 Clinical Results associated with VSA012

Login to view more data

100 Translational Medicine associated with VSA012

Login to view more data

100 Patents (Medical) associated with VSA012

Login to view more data

100 Deals associated with VSA012

Login to view more data